0001493152-26-011625
SEC filingBiofrontera Inc. (BFRI) reported FY 2025 net revenues of $41.7 million, up 11.8% YoY from $37.3 million, driven by $4.1 million organic growth in Ameluz sales volume and $0.7 million from higher unit pricing, partially offset by lower RhodoLED lamp sales. Total operating expenses declined to $53.1 million from $54.5 million, primarily due to a 43.4% drop in related-party cost of revenues to $10.1 million following the October 2025 Strategic Transaction acquiring U.S. rights to Ameluz and RhodoLED, which reduced per-unit costs to ~5%. Loss from operations improved to -$11.3 million from -$17.2 million. Net loss narrowed to -$10.5 million from -$17.8 million, with basic EPS at -$1 on 10.2 million weighted-average shares. Cash used in operations was $13.4 million, offset by $3.0 million investing inflow from Xepi asset sale and $10.8 million financing from preferred stock issuances, yielding a net cash increase of $0.5 million to $6.4 million. Total assets stood at $28.6 million, with stockholders' equity at $10.5 million. Management highlights going concern doubts due to liquidity, plans commercialization expansion, label extensions, and additional financing amid Nasdaq bid price compliance issues.
Biofrontera Inc. delivered improved FY 2025 results with net revenues of $41.7M, a 11.8% YoY increase from $37.3M, fueled by Ameluz growth despite GPO pressures. Loss from operations narrowed to -$11.3M from -$17.2M, aided by lower cost of revenues ($11.0M total). Net loss reduced to -$10.5M from -$17.8M, reflecting Strategic Transaction benefits and cost controls. Adjusted EBITDA loss improved to -$10.6M from -$15.3M, with margin expanding to -25.4% from -40.9%. Employees totaled 92 as of Dec 31, 2025. Nasdaq non-compliance notice issued Dec 31, 2025, for bid price < $1.00, with 180 days to comply.
Product revenues, net of $41.7M primarily from Ameluz ($41.7M total net, including minor related-party $18K). YoY growth: +$4.4M, with Ameluz volume +$4.1M, pricing +$0.7M; RhodoLED lamps declined $0.3M post-BF-RhodoLED XL launch surge. No single customer >10% of revenues or receivables. Sales direct to U.S. dermatology offices. Strategic Transaction (Oct 20, 2025) acquired U.S. rights to Ameluz/RhodoLED, shifting to earnout (12-15% of U.S. sales).
Cost of revenues $11.0M (related-party $10.1M down 43.4% YoY post-transaction; other $0.9M). Implied gross profit $30.7M (73.6% margin, up from prior due to lower per-unit costs ~5% vs. 25-50%). SG&A $37.8M (+11.7% YoY, driven by $6.6M legal/patent costs, offset by sales headcount cuts). R&D $3.7M (+78% YoY from clinical trial control since Jun 2024). Operating margin -27.1% (improved from -46.1%).
Operating cash use $13.4M (net loss -$10.5M, working capital outflow -$3.5M). Investing +$3.0M (Xepi sale). Financing +$10.8M (Series C preferred $10.8M, Series B issuances/exercises $15.1M, convertible notes $4.0M, offset by debt paydown $4.3M). Ending cash $6.4M (net +$0.5M). Total assets $28.6M (current $18.1M). Liabilities $18.1M (current $11.9M, incl. related-party payables $6.7M; convertible notes $4.6M). Equity $10.5M (accumulated deficit -$127.9M). Going concern doubt noted; unaudited cash $3.6M as of Mar 11, 2026.
Strategy: Expand Ameluz/RhodoLED sales, pursue label expansions (AK, acne, basal cell carcinoma), improve lamps, add complementary IP. R&D focuses on trials via subsidiary Discovery. Plans: Commercial growth, cost control, $1.0M Xepi milestone, additional financing. Risks: Generic Ameluz entry post-patents (2027-2043), IP litigation, reimbursement, GPOs, tariffs, going concern, Nasdaq delisting potential.